The University of Chicago Header Logo

Connection

Anand Patel to Myeloproliferative Disorders

This is a "connection" page, showing publications Anand Patel has written about Myeloproliferative Disorders.
Connection Strength

3.553
  1. Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
    View in: PubMed
    Score: 0.781
  2. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
    View in: PubMed
    Score: 0.781
  3. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
    View in: PubMed
    Score: 0.673
  4. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
    View in: PubMed
    Score: 0.673
  5. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.646
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.